Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Change in Account Payables (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Change in Account Payables for 15 consecutive years, with $230209.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables rose 24.13% year-over-year to $230209.0, compared with a TTM value of $438760.0 through Sep 2025, up 152.13%, and an annual FY2024 reading of $293680.0, up 1488.58% over the prior year.
  • Change in Account Payables was $230209.0 for Q3 2025 at BioRestorative Therapies, up from $10430.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $230209.0 in Q3 2025 and bottomed at -$297599.0 in Q4 2022.
  • Average Change in Account Payables over 5 years is $37962.5, with a median of $41513.0 recorded in 2024.
  • The sharpest move saw Change in Account Payables plummeted 362.59% in 2021, then surged 480.87% in 2024.
  • Year by year, Change in Account Payables stood at -$73731.0 in 2021, then plummeted by 303.63% to -$297599.0 in 2022, then surged by 87.24% to -$37966.0 in 2023, then skyrocketed by 315.17% to $81690.0 in 2024, then soared by 181.81% to $230209.0 in 2025.
  • Business Quant data shows Change in Account Payables for BRTX at $230209.0 in Q3 2025, $10430.0 in Q2 2025, and $116431.0 in Q1 2025.